ADVANZ PHARMA GENERICS (UK) LIMITED
Get an alert when ADVANZ PHARMA GENERICS (UK) LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£2.1m
+61.5% vs 2024
Net assets
£14m
+15% highest in 3 filed years
Employees
—
Average over period
Profit before tax
£1.8m
+23.6% vs 2024
Net assets
3-year trend · vs Health Care median
Accounts
3-year trend · Δ = latest vs prior filed period · latest reflected 2025-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 | 2025-12-31 | Δ vs prior |
|---|---|---|---|---|---|
| Turnover | £46,596,000 | £45,062,000 | £55,831,000 | +23.9% | |
| Operating profit | £2,000,000 | £1,347,000 | £1,689,000 | +25.4% | |
| Profit before tax | £2,072,000 | £1,434,000 | £1,773,000 | +23.6% | |
| Net profit | £2,072,000 | £1,434,000 | £1,773,000 | +23.6% | |
| Cash | £3,711,000 | £1,286,000 | £2,077,000 | +61.5% | |
| Total assets less current liabilities | — | £11,811,000 | £13,584,000 | +15% | |
| Net assets | £10,377,000 | £11,811,000 | £13,584,000 | +15% | |
| Equity | £10,377,000 | £11,811,000 | £13,584,000 | +15% | |
| Average employees | 106 | 113 | — | — | |
| Wages | — | — | — | — | |
| Directors' remuneration | — | — | — | — |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Operating margin | 4.3% | 3.0% | 3.0% | |
| Net margin | 4.4% | 3.2% | 3.2% | |
| Return on capital employed | — | 11.4% | 12.4% | |
| Gearing (liabilities / total assets) | — | 47.8% | 26.8% | |
| Current ratio | 1.70x | 2.09x | 3.74x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Name history
Renamed 5 times since incorporation
- ADVANZ PHARMA GENERICS (UK) LIMITED 2018-10-30 → present
- MERCURY PHARMA (GENERICS) LIMITED 2012-03-20 → 2018-10-30
- FORLEY GENERICS LIMITED 1999-08-26 → 2012-03-20
- GOLDSHIELD FORLEY LIMITED 1999-08-13 → 1999-08-26
- GOLDSHIELD GENERICS LIMITED 1997-05-13 → 1999-08-13
- GAMAACE LIMITED 1992-10-30 → 1997-05-13
Audit & accounting basis
- Accounting basis
- FRS 101
- Reporting scope
- Standalone (parent only)
- Auditor
- Grant Thornton
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The financial statements have been prepared on the going concern basis, which assumes that the Company will be able to realise its assets and discharge its liabilities in the normal course of operations as they fall due. The Company's Intermediate Holding Company, APHL has provided the Company with a letter of support indicating its intention to provide financial support required for a period of at least 12 months from the date these financial statements are approved. After making enquiries, considering the Group's forecasts and projections and considering the letter of support received from APHL, the directors have a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
3 active · 23 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| TMF CORPORATE ADMINISTRATION SERVICES LIMITED | Corporate Secretary | 2022-03-16 | — | — |
| FERRY, Melvin Jeremy, Mr. | Director | 2025-02-06 | Jun 1982 | British |
| STICKLER, Andreas | Director | 2022-01-21 | Feb 1971 | German |
Show 23 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| FARLEY, Joe | Secretary | 1998-04-28 | 2004-12-03 |
| MYRANTS, George, Mr. | Secretary | 1993-01-25 | 1998-04-29 |
| SULLY, Robert | Secretary | 2018-10-01 | 2022-03-16 |
| SULLY, Robert James | Secretary | 2011-07-25 | 2016-12-31 |
| VENKATESWARAN, Subramanian | Secretary | 2004-12-03 | 2011-06-24 |
| WILLIAMS, David Richard | Secretary | 2016-12-31 | 2018-10-01 |
| ELK COMPANY SECRETARIES LIMITED | Corporate Nominee Secretary | 1992-10-30 | 1993-01-25 |
| AHMAD, Adeel | Director | 2016-01-08 | 2022-01-31 |
| BEIGHTON, John, Mr. | Director | 2010-09-08 | 2016-12-31 |
| DUNCAN, Graeme Neville | Director | 2018-11-30 | 2022-01-12 |
| DUNCAN, Graeme Neville | Director | 2017-06-19 | 2018-03-08 |
| KAMATH, Vikram Laxman | Director | 2012-10-23 | 2025-02-06 |
| MYRANTS, George, Mr. | Director | 1993-01-25 | 1998-04-29 |
| MYRANTS, Sandra Anne | Director | 1993-01-25 | 1998-04-29 |
| PATEL, Ajay Mafatlal | Director | 2000-01-04 | 2010-08-31 |
| PATEL, Ajit Ramanlal | Director | 1998-04-29 | 2007-07-02 |
| PATEL, Kirti Vinubhai | Director | 1998-04-29 | 2007-12-31 |
| PATEL, Rakesh Vinodrai | Director | 2000-01-04 | 2010-05-19 |
| RAMAN, Anand | Director | 2011-01-26 | 2012-10-23 |
| SCHWALBER, Philipp Theodor | Director | 2010-03-02 | 2012-04-18 |
| STONE, Lisa | Director | 2010-03-02 | 2012-04-18 |
| VAN TIGGELEN, Antonie Pieter | Director | 2013-09-25 | 2016-01-08 |
| ELK (NOMINEES) LIMITED | Corporate Nominee Director | 1992-10-30 | 1993-01-25 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Mercury Pharma Group Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2021-06-01 | Active |
| The Blackstone Group Inc. | Corporate entity | Shares 25–50%, Voting 25–50% | 2020-03-27 | Ceased 2021-06-01 |
| Mercury Pharma Group Limited | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2018-08-10 | Ceased 2020-03-27 |
Filing timeline
Last 20 of 182 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-08-03 | AA | accounts | Accounts with accounts type full | |
| 2026-07-20 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-07-21 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-06-30 | AA | accounts | Accounts with accounts type full | |
| 2025-02-20 | AP01 | officers | Appoint person director company with name date | |
| 2025-02-19 | TM01 | officers | Termination director company with name termination date | |
| 2024-09-02 | AA | accounts | Accounts with accounts type full | |
| 2024-07-31 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-08-17 | PSC05 | persons-with-significant-control | Change to a person with significant control | |
| 2023-08-03 | AA | accounts | Accounts with accounts type full | |
| 2023-08-02 | CH01 | officers | Change person director company with change date | |
| 2023-08-01 | AD01 | address | Change registered office address company with date old address new address | |
| 2023-07-27 | CH04 | officers | Change corporate secretary company with change date | |
| 2023-07-26 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2023-07-21 | CH01 | officers | Change person director company with change date | |
| 2022-09-30 | AA | accounts | Accounts with accounts type full | |
| 2022-07-15 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-03-28 | AP04 | officers | Appoint corporate secretary company with name date | |
| 2022-03-28 | TM02 | officers | Termination secretary company with name termination date | |
| 2022-02-02 | AP01 | officers | Appoint person director company with name date |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 2
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.